Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

See less

Articles from Colin

Approximately 13% of hospitalized COVID patients have serious neurologic symptoms

In a recent study in the journal Critical Care Explorations, the Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry was used to record significant neurologic signs of SARS-CoV-2 infection, as well as prehospital risk factors and outcomes.

9 May 2022

The impact of COVID-19 on digital health adoption

A new study analyzed the impact that coronavirus disease 2019 has had on the adoption of digital health.

5 May 2022

Study explores SARS-CoV-2 RNA genome's functional interactions with host cell

In a new study, a worldwide map of the SARS-CoV-2 genome-associated host proteins was developed by a team of researchers using the identification of RNA-binding protein by MS (ChIRP-MS) technique.

3 May 2022

Exploring oncolytic viral therapeutics and immunotherapies derived from DNA and RNA

A new review initially described the developments in cancer-based medicines that included vaccinations, vector-based techniques, and genome injection using DNA and RNA-based nucleic acid therapeutics.

28 Apr 2022

CRISPR/Cas9 deletions induce adverse on-target genomic effects

Researchers utilized a CRISPR/Cas9 system to evaluate the usage of tRNA by deleting two tRNA genes from the genomes of hyper hepatocellular carcinoma and human near-haploid chronic myeloid leukemia cells.

27 Apr 2022